Skip to content
Screener

Niagen Bioscience NAGE Q1 2025 earnings

Reported May 7, 2025 · After market close

Revenue$30.5MBeat by $3.4M
EPS$0.04Beat by $0.02
Revenue estimate$27.1M
EPS estimate$0.02

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$34.4M
EPS estimate$0.01

Financials

Q1 2025

Income statement

See full
Revenue$30.5M+37.6%
Gross profit$19.3M+43.7%
Operating income$4.8M+753%
Net income$5.1M+1,129%
EPS (diluted)$0.06+700%

Balance sheet

See full
Cash & equivalents$55.6M+102%
Total debt$3.5M+9.2%
Total equity$55.3M+91.2%
Total assets$81.3M+50.4%

Cash flow

See full
Operating cash flow$7.9M+2,572%

Valuation & ratios

Profitability

See full
Gross margin62.5%+1.5pp
Operating margin12.3%+9.4pp
Net margin13.1%+10.4pp

Returns & leverage

See full
Return on equity33.5%+26.2pp
Debt / equity0.1×0.0×
Current ratio3.7×+1.1×

Segments

By segment

See full
Consumer Products segment$21.5M+23.9%
Ingredients segment$8.2M+99.8%
Analytical Reference Standards and Services segment$811.0K+13.6%
Pharmaceuticals segment-—

FAQ

When did Niagen Bioscience report Q1 2025 earnings?
Niagen Bioscience (NAGE) reported Q1 2025 earnings on May 7, 2025 after market close.
What were Niagen Bioscience's Q1 2025 revenue and EPS?
Niagen Bioscience reported revenue of $30.5M and eps of $0.04 for Q1 2025.
Did Niagen Bioscience beat estimates in Q1 2025?
Revenue beat the consensus estimate of $27.1M by $3.4M. EPS beat the consensus estimate of $0.02 by $0.02.
Where can I find Niagen Bioscience's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-023129) and the 10-Q periodic report (0001628280-25-023127) directly on SEC EDGAR. The filing index links above go to sec.gov.